Modern approaches to HLA-haploidentical blood or marrow transplantation
CG Kanakry, EJ Fuchs, L Luznik - Nature reviews Clinical oncology, 2016 - nature.com
Allogeneic blood or bone-marrow transplantation (alloBMT) is a potentially curative
treatment for a variety of haematological malignancies and nonmalignant diseases …
treatment for a variety of haematological malignancies and nonmalignant diseases …
How I prevent GVHD in high-risk patients: posttransplant cyclophosphamide and beyond
J Rimando, SR McCurdy, L Luznik - Blood, 2023 - ashpublications.org
Advances in conditioning, graft-versus-host disease (GVHD) prophylaxis and antimicrobial
prophylaxis have improved the safety of allogeneic hematopoietic cell transplantation (HCT) …
prophylaxis have improved the safety of allogeneic hematopoietic cell transplantation (HCT) …
Posttransplantation cyclophosphamide prevents graft-versus-host disease by inducing alloreactive T cell dysfunction and suppression
LP Wachsmuth, MT Patterson… - The Journal of …, 2019 - Am Soc Clin Investig
Posttransplantation cyclophosphamide (PTCy) recently has had a marked impact on human
allogeneic hematopoietic cell transplantation (HCT). Yet our understanding of how PTCy …
allogeneic hematopoietic cell transplantation (HCT). Yet our understanding of how PTCy …
Posttransplant cyclophosphamide vs antithymocyte globulin in HLA-mismatched unrelated donor transplantation
The use of anti-thymocyte globulin (ATG) has represented the standard of care in graft-
versus-host disease (GVHD) prophylaxis in patients undergoing a mismatched unrelated …
versus-host disease (GVHD) prophylaxis in patients undergoing a mismatched unrelated …
Post-transplant cyclophosphamide for graft-versus-host disease prophylaxis in HLA matched sibling or matched unrelated donor transplant for patients with acute …
A Ruggeri, M Labopin, A Bacigalupo… - Journal of hematology & …, 2018 - Springer
Background Experience using post-transplant cyclophosphamide (PT-Cy) as graft-versus-
host disease (GVHD) prophylaxis in allogeneic stem cell transplantation (HSCT) from …
host disease (GVHD) prophylaxis in allogeneic stem cell transplantation (HSCT) from …
[HTML][HTML] Graft-versus-host disease prophylaxis in unrelated peripheral blood stem cell transplantation with post-transplantation cyclophosphamide, tacrolimus, and …
IS Moiseev, OV Pirogova, AL Alyanski… - Biology of Blood and …, 2016 - Elsevier
Clinical efficacy of post-transplantation cyclophosphamide (PTCy) as graft-versus-host
disease (GVHD) prophylaxis has been demonstrated in haploidentical and HLA-matched …
disease (GVHD) prophylaxis has been demonstrated in haploidentical and HLA-matched …
[HTML][HTML] Reduced-intensity conditioning and dual T lymphocyte suppression with antithymocyte globulin and post-transplant cyclophosphamide as graft-versus-host …
AD Law, MQ Salas, W Lam, FV Michelis… - Biology of Blood and …, 2018 - Elsevier
Haploidentical hematopoietic stem cell transplantation (haploHSCT) with conditioning
regimens using post-transplant cyclophosphamide (PTCy) for peripheral blood stem cell …
regimens using post-transplant cyclophosphamide (PTCy) for peripheral blood stem cell …
Low immunosuppressive burden after HLA-matched related or unrelated BMT using posttransplantation cyclophosphamide
CG Kanakry, J Bolaños-Meade… - Blood, The Journal …, 2017 - ashpublications.org
The intensive and prolonged immunosuppressive therapy required to prevent or treat graft-
versus-host disease (GVHD) after allogeneic blood or marrow transplantation (alloBMT) puts …
versus-host disease (GVHD) after allogeneic blood or marrow transplantation (alloBMT) puts …
Post‐transplantation cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation from …
BACKGROUND Graft‐versus‐host disease (GVHD) is a major complication after allogeneic
hematopoietic stem cell transplantation (allo‐HSCT). Addition of antithymocyte globulin …
hematopoietic stem cell transplantation (allo‐HSCT). Addition of antithymocyte globulin …
Post-transplantation cyclophosphamide: from HLA-haploidentical to matched-related and matched-unrelated donor blood and marrow transplantation
L Williams, F Cirrone, K Cole, M Abdul-Hay… - Frontiers in …, 2020 - frontiersin.org
Following allogeneic blood and marrow transplantation (BMT), graft-versus-host disease
(GvHD) continues to represent a significant cause of treatment failure, despite the routine …
(GvHD) continues to represent a significant cause of treatment failure, despite the routine …